Acute Iv CRH Administration Significantly Increases Serum Active Ghrelin in Postmenopausal PCOS Women Compared to Postmenopausal Controls

Overview

Journal Endocrine

Specialty Endocrinology

Date 2023 May 30

PMID 37249728

Authors

Marios Markopoulos

Thomas M Barber

Alexandra Bargiota

Chrysanthi Skevaki

Ioannis Papassotiriou

Sudhesh Kumar

Nikos F Vlahos

George Mastorakos

Georgios Valsamakis

Affiliations

Soon will be listed here.

Abstract

Purpose: In women with Polycystic Ovarian Syndrome (PCOS), an increased risk of disordered eating has been described. There is growing interest regarding a possible interconnection between psychological states and increased appetite in women with PCOS. Acute stress is characterized by increased Corticotropin Releasing Hormone (CRH) secretion. The aim was to estimate the ghrelin concentrations during CRH test.

Methods: Twenty postmenopausal women with PCOS and twenty age- and BMI- matched postmenopausal control women were recruited at Aretaieion University Hospital. In the morning (9 am) all subjects had anthropometric measurements (weight, height, waist circumference) and a fasting sample for hormonal measurements. An intravenous (iv) CRH stimulation test conducted over 1 min. Serum active ghrelin levels were measured at 0, 15, 30, 60, 90, 120 min after iv CRH administration.

Results: The postmenopausal PCOS group had a higher waist circumference compared to postmenopausal controls. Active ghrelin concentrations increased significantly from 0 to 15 min, to 30 min, to 60 min, to 90 min and then decreased to 120 min. However, within the postmenopausal control group there were no significant changes in serum active ghrelin levels. Serum active ghrelin concentrations were significantly greater in the postmenopausal control group at 0, 15 and 120 min compared to the postmenopausal PCOS group. At 90 min active ghrelin concentrations were significantly greater in the postmenopausal PCOS group. Delta Area Under the Curve of active ghrelin (ΔAUCghr) was significantly greater in the postmenopausal PCOS group compared to controls.

Conclusions: In postmenopausal PCOS, but not in postmenopausal controls, iv CRH administration induces increased serum active ghrelin secretion, suggesting a possible anti-stress adaptive mechanism. An increase in serum active ghrelin may induce hunger as a side-effect of this presumed adaptive mechanism.

References

Goodman N, Cobin R, Futterweit W, Glueck J, Legro R, Carmina E . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, AMERICAN COLLEGE OF ENDOCRINOLOGY, AND ANDROGEN EXCESS AND PCOS SOCIETY DISEASE STATE CLINICAL REVIEW: GUIDE TO THE BEST PRACTICES IN THE EVALUATION AND TREATMENT OF POLYCYSTIC OVARY SYNDROME--PART 1. Endocr Pract. 2015; 21(11):1291-300. DOI: 10.4158/EP15748.DSC. View

Lee I, Cooney L, Saini S, Smith M, Sammel M, Allison K . Increased risk of disordered eating in polycystic ovary syndrome. Fertil Steril. 2017; 107(3):796-802. DOI: 10.1016/j.fertnstert.2016.12.014. View

Damone A, Joham A, Loxton D, Earnest A, Teede H, Moran L . Depression, anxiety and perceived stress in women with and without PCOS: a community-based study. Psychol Med. 2018; 49(9):1510-1520. DOI: 10.1017/S0033291718002076. View

Kim J, Han S, Iremonger K . Stress experience and hormone feedback tune distinct components of hypothalamic CRH neuron activity. Nat Commun. 2019; 10(1):5696. PMC: 6911111. DOI: 10.1038/s41467-019-13639-8. View

Weninger S, Dunn A, Muglia L, Dikkes P, Miczek K, Swiergiel A . Stress-induced behaviors require the corticotropin-releasing hormone (CRH) receptor, but not CRH. Proc Natl Acad Sci U S A. 1999; 96(14):8283-8. PMC: 22226. DOI: 10.1073/pnas.96.14.8283. View

Basu B, Chowdhury O, Saha S . Possible Link Between Stress-related Factors and Altered Body Composition in Women with Polycystic Ovarian Syndrome. J Hum Reprod Sci. 2018; 11(1):10-18. PMC: 5892097. DOI: 10.4103/jhrs.JHRS_78_17. View

Moran L, Noakes M, Clifton P, Wittert G, Tomlinson L, Galletly C . Ghrelin and measures of satiety are altered in polycystic ovary syndrome but not differentially affected by diet composition. J Clin Endocrinol Metab. 2004; 89(7):3337-44. DOI: 10.1210/jc.2003-031583. View

Teede H, Joham A, Paul E, Moran L, Loxton D, Jolley D . Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity (Silver Spring). 2013; 21(8):1526-32. DOI: 10.1002/oby.20213. View

Hajivandi L, Noroozi M, Mostafavi F, Ekramzadeh M . Food habits in overweight and obese adolescent girls with Polycystic ovary syndrome (PCOS): a qualitative study in Iran. BMC Pediatr. 2020; 20(1):277. PMC: 7271429. DOI: 10.1186/s12887-020-02173-y. View

10.

Muccioli G, Tschop M, Papotti M, Deghenghi R, Heiman M, Ghigo E . Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol. 2002; 440(2-3):235-54. DOI: 10.1016/s0014-2999(02)01432-2. View

11.

Schofl C, Horn R, Schill T, Schlosser H, Muller M, Brabant G . Circulating ghrelin levels in patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002; 87(10):4607-10. DOI: 10.1210/jc.2002-020505. View

12.

Rodin J . Insulin levels, hunger, and food intake: an example of feedback loops in body weight regulation. Health Psychol. 1985; 4(1):1-24. DOI: 10.1037//0278-6133.4.1.1. View

13.

Markopoulos M, Valsamakis G, Kouskouni E, Boutsiadis A, Papassotiriou I, Creatsas G . Study of carbohydrate metabolism indices and adipocytokine profile and their relationship with androgens in polycystic ovary syndrome after menopause. Eur J Endocrinol. 2012; 168(1):83-90. DOI: 10.1530/EJE-12-0550. View

14.

Azziz R . Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab. 2006; 91(3):781-5. DOI: 10.1210/jc.2005-2153. View

15.

Chrousos G, Schulte H, Oldfield E, Gold P, Cutler Jr G, Loriaux D . The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome. N Engl J Med. 1984; 310(10):622-6. DOI: 10.1056/NEJM198403083101004. View

16.

Dunbar S . Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta. 2005; 363(1-2):71-82. PMC: 7124242. DOI: 10.1016/j.cccn.2005.06.023. View

17.

Liu S, Gao X, Gao N, Wang X, Fang X, Hu H . Expression of type 1 corticotropin-releasing factor receptor in the guinea pig enteric nervous system. J Comp Neurol. 2004; 481(3):284-98. DOI: 10.1002/cne.20370. View

18.

Chatzaki E, Murphy B, Wang L, Million M, Ohning G, Crowe P . Differential profile of CRF receptor distribution in the rat stomach and duodenum assessed by newly developed CRF receptor antibodies. J Neurochem. 2003; 88(1):1-11. DOI: 10.1046/j.1471-4159.2003.02078.x. View

19.

Chatzaki E, Lambropoulou M, Constantinidis T, Papadopoulos N, Tache Y, Minopoulos G . Corticotropin-releasing factor (CRF) receptor type 2 in the human stomach: protective biological role by inhibition of apoptosis. J Cell Physiol. 2006; 209(3):905-11. DOI: 10.1002/jcp.20792. View

20.

Porcher C, Peinnequin A, Pellissier S, Meregnani J, Sinniger V, Canini F . Endogenous expression and in vitro study of CRF-related peptides and CRF receptors in the rat gastric antrum. Peptides. 2005; 27(6):1464-75. DOI: 10.1016/j.peptides.2005.10.023. View